Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-α treatment for chronic hepatitis C

Internal Medicine

Volumn 49, Issue 5, 2010, Pages 403-407

  Yamazaki, Masanori ^a   Sato, Ai ^a   Takeda, Teiji ^a   Komatsu, Mitsuhisa ^a  

^a SHINSHU UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Type 1 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN ASPART; PEGINTERFERON ALPHA; RHEUMATOID FACTOR; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CELL FUNCTION; CONVALESCENCE; DIET RESTRICTION; DISEASE COURSE; GLYCEMIC CONTROL; HASHIMOTO DISEASE; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SJOEGREN SYNDROME; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MIDDLE AGED; POLYETHYLENE GLYCOLS; SJOGREN'S SYNDROME;

EID: 77749261899     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2656     Document Type: Article

References (16)

1. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204: 9-26, 2005.
2. Bartolomé J, Rodriguez-Inigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV
3. infection. J Med Virol 80: 1588-1594, 2008.
4. Nordmark G, Alm GV, Ronnblom L. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2: 262-269, 2006.
5. Masini M, Campani D, Boggi U, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 28: 940-941, 2005.
6. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. Diabet Med 22: 340-343, 2005.
7. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18: 549-558, 2003.
8. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 105: 12439-12444, 2008.
9. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 28: 39-46, 2008.
10. Watanabe J, Yamauchi T. A case of type 1 diabetes mellitus with high titer anti-GAD antibody after combined interferon and ribavirin therapy for chronic hepatitis C. Tonyobyo (Diabetes) 50: 753-757, 2007 (in Japanese, Abstract in English).
11. Betterle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 23: 1177-1181, 2000.
12. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 23: 33-36, 1994.
13. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract 30: 237-241, 1995.
14. Karges B, Durinovic-Bello I, Heinze E, Debatin KM, Boehm B, Karges W. Immunological mechanisms associated with long-term remission of human type 1 diabetes. Diabetes Metab Res Rev 22: 184-189, 2006.
15. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic betacells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103: 9232-9237, 2006.
16. Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 118: 58-65, 2006.